Bavarian Nordic’s Chikungunya Vaccine Submitted for Regulatory Approval in Brazil

Eurofarma has submitted a marketing authorization application to Brazil's Anvisa for Bavarian Nordic's chikungunya vaccine (CHIKV VLP) for individuals 12 years and older. The submission marks a key milestone in their partnership and addresses Brazil's significant burden of chikungunya cases, which account for over half of global reported cases and deaths.